Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| TCG Crossover Management, LLC | 9.53M | $67.0M | 9.21% | -- | 2026-06-30 |
| MONTANOVA CAPITAL, LLC | 7.21M | $51.0M | 6.96% | +2.83M | 2026-06-30 |
| Frazier Life Sciences Management, L.P. | 7.10M | $50.0M | 6.86% | +2.00M | 2026-06-30 |
| Long Focus Capital Management, LLC | 5.12M | $36.0M | 4.95% | +500.0K | 2026-06-30 |
| BlackRock, Inc. | 4.71M | $33.0M | 4.55% | +1.12M | 2026-06-30 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.64M | $32.0M | 4.48% | -241.1K | 2026-06-30 |
| Caligan Partners LP | 4.30M | $30.0M | 4.15% | +4.07M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 4.10M | $29.0M | 3.96% | +1.86M | 2026-06-30 |
| FCPM III SERVICES B.V. | 4.05M | $28.0M | 3.92% | -- | 2026-06-30 |
| ORBIMED ADVISORS LLC | 3.33M | $23.0M | 3.22% | -- | 2026-06-30 |
